资源类型:
会议/期刊
收录情况:
◇ SCIE
文章类型:
会议摘要
作者:
Chen, Wenming[1]
*
;
Xia, Zhongjun[2]
;
Fang, Baijun[3]
;
Fu, Chengcheng[4]
;
Li, Wei[5]
;
Yang, Linhua[6]
;
Ke, Xiaoyan[7,8]
;
Jiang, Hua[9]
;
Weng, Jianyu[10]
;
Liu, Li[11]
;
Zhao, Yaozhong[12]
;
Zhang, Xuejun[6]
;
Liu, Aichun[13]
;
Huang, Zhongxia[1]
;
Shi, Qingzhi[14]
;
Gao, Yuhuan[15]
;
Chen, Xiequn[16]
;
Pan, Ling[17]
;
Cai, Zhen[18]
;
Wang, Zhao[19]
;
Wang, Yafei[20]
;
Zhang, Yizhuo[20]
;
Fan, Yaqun[21,22]
;
Hou, Ming[23]
;
Yang, Shifang[24]
;
单位:
[1]Capital Med Univ, Beijing Chaoyang Hosp, Dept Hematol, Beijing, Peoples R China
北京朝阳医院
[2]Sun Yat Sen Univ, Ctr Canc, Dept Hematol, Guangzhou, Peoples R China
[3]Zhengzhou Univ, Henan Canc Hosp, Dept Hematol Oncol, Zhengzhou, Peoples R China
河南省肿瘤医院
[4]Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis,Dept Hematol, Suzhou, Peoples R China
[5]First Hosp Jilin Univ, Ctr Oncol, Dept Hematol, Changchun, Peoples R China
[6]Shanxi Med Univ, Hosp 2, Dept Hematol, Xian, Peoples R China
[7]Peking Univ, Hosp 3, Dept Hematol, Beijing, Peoples R China
[8]Peking Univ, Hosp 3, Lymphoma Res Ctr, Beijing, Peoples R China
[9]Second Mil Med Univ, Chang Zheng Hosp, Dept Hematol, Shanghai, Peoples R China
[10]Guangdong Acad Med Sci, Guangdong Gen Hosp, Dept Hematol, Guangzhou, Peoples R China
广东省人民医院
[11]Fourth Mil Med Univ, Tangdu Hosp, Dept Hematol, Xian, Peoples R China
[12]Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Dept Lymphoma Ctr, Beijing, Peoples R China
[13]Harbin Med Univ Canc Hosp, Dept Hematol, Harbin, Peoples R China
[14]Nanchang Univ, Dept Hematol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
[15]Hebei Med Univ, Hosp 4, Dept Hematol, Wuhan, Peoples R China
河北医科大学第四医院
[16]Fourth Mil Med Univ, Xijing Hosp, Dept Hematol, Xian, Peoples R China
[17]Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China
四川大学华西医院
[18]Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
浙江大学医学院附属第一医院
[19]Capital Med Univ, Beijing Friendship Hosp, Dept Hematol, Beijing, Peoples R China
临床科室
血液科
血液科
首都医科大学附属北京友谊医院
[20]Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Hematol, Tianjin, Peoples R China
[21]Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China
[22]Xiamen Univ, Inst Hematol, Coll Med, Dept Hematol, Xiamen, Peoples R China
[23]Shandong Univ, Qilu Hosp, Dept Hematol, Jinan, Peoples R China
[24]Beijing Sunbio Biotech Co Ltd, Beijing, Peoples R China
出处:
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA.2021,21:S143-S143.
ISSN:
2152-2650
WOS:
WOS:000717640800246
中科院(CAS)分区:
出版当年[2020]版:
大类
|
4 区
医学
小类
|
4 区
血液学
4 区
肿瘤学
最新[2025]版:
大类
|
4 区
医学
小类
|
4 区
血液学
4 区
肿瘤学
JCR分区:
出版当年[2019]版:
Q3
ONCOLOGY
Q3
HEMATOLOGY
最新[2023]版:
Q2
HEMATOLOGY
Q3
ONCOLOGY
影响因子:
最新[2023版] 2.7
最新五年平均[2021-2025] 2.4
出版当年[2019版] 2.298
出版当年五年平均[2015-2019] 2.177
出版前一年[2018版] 2.274
出版后一年[2020版] 3.231
第一作者:
Chen, Wenming
第一作者单位:
[1]Capital Med Univ, Beijing Chaoyang Hosp, Dept Hematol, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
Chen Wenming,Xia Zhongjun,Fang Baijun,et al.Circularly permuted TRAIL (CPT) combined with Thalidomide and Dexamethasone in patients with relapsed/refractory Multiple Myeloma: a randomized, double-blind, placebo-controlled phase 3 study[J].CLINICAL LYMPHOMA MYELOMA & LEUKEMIA.2021,21:S143-S143.
APA:
Chen, Wenming,Xia, Zhongjun,Fang, Baijun,Fu, Chengcheng,Li, Wei...&Yang, Shifang.(2021).Circularly permuted TRAIL (CPT) combined with Thalidomide and Dexamethasone in patients with relapsed/refractory Multiple Myeloma: a randomized, double-blind, placebo-controlled phase 3 study.CLINICAL LYMPHOMA MYELOMA & LEUKEMIA,21,
MLA:
Chen, Wenming,et al."Circularly permuted TRAIL (CPT) combined with Thalidomide and Dexamethasone in patients with relapsed/refractory Multiple Myeloma: a randomized, double-blind, placebo-controlled phase 3 study".CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 21.(2021):S143-S143